Rafael Holdings — Fiscal Year 2026 Earnings Summary

Rafael Holdings reported a net loss of $9.2 million for the fourth quarter of fiscal 2026 and $29.6 million for the full fiscal year ended July 31, 2026. The company submitted a New Drug Application to the FDA in October 2026 for remibetadex to treat Niemann-Pick Disease Type C, supported by Phase 3 data showing slowed disease progression in a specific patient subgroup. General and administrative expenses decreased significantly year-over-year due to reduced payroll, stock-based compensation, and professional fees, while research and development expenses increased following the consolidation of Cyclo Therapeutics. As of July 31, 2026, the company held $22.1 million in cash and cash equivalents.